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Abstract 
 
 Advances in anti-retroviral therapy over the last two decades have allowed 
life expectancy in patients infected with the human immunodeficiency virus to 
approach that of the general population.  The process of aging in mammalian 
species, including rats, results in changes with immune response, immunological 
phenotypes, and ultimately, increased susceptibility to many infectious diseases.  
In order to investigate the immunological pathologies associated with chronic 
HIV-1 disease, particularly in aged individuals, the HIV-1 transgenic (HIV-1Tg) rat 
model was utilized. Age matched animals were challenged using 
lipopolysaccharide (LPS) to determine immunological modification of HIV-1Tg 
animals throughout the aging process.  LPS is known to cause imbalances in 
cytokine and chemokine release, and provides a method to identify alterations of 
immune response to bacterial infection. In the HIV-1Tg rats, the percentage of T 
cells decreased with aging, particularly with T cytotoxic cells, whereas T helper 
cells were increased with age.  Neutrophil and monocyte cell numbers increased 
in HIV-1Tg rats during maturation compared to age-matched control rats.  Aging 
HIV-1Tg rats displayed a significant increase in the pro-inflammatory cytokines, 
IL-6 and TNF-α in comparison to age-matched controls.  Our data indicate that 
the immunophenotype and immune responses can change during aging in HIV-
positive individuals.  This information could be important in determining the most 
beneficial age-dependent therapeutic treatment for HIV patients.
1 
Introduction 
 
 
Life expectancy of people infected with the human immunodeficiency virus 
(HIV) is increasing and approximates that of the general population.  The current 
median life expectancy for an HIV patient receiving effective therapy exceeds 70 
years of age (High et al., 2012).  In the United States, estimates indicate that, by 
2015, most of the patients diagnosed with HIV will be 50 years of age and older 
(Mills et al., 2012; Nath, 2012).  A recent publication from the United Kingdom 
reported that the percentage of HIV-positive individuals who are over 50 years of 
age has risen from 12% in 2002 to 22% in 2011 due to an increase in length of 
survival and a surge in the incidence of newly identified older HIV patients 
(Health Protection Agency, 2012).  Furthermore, a majority of the older patients 
were aware of their HIV status for at least a decade, and were being treated with 
anti-retroviral therapy since testing positive.  However, as the population of HIV-
positive patients ages, they often develop other ailments, including 
cardiovascular disease, cancer, osteoporosis, and liver and renal disease, as 
well as the neurocognitive deficiencies more commonly associated with aging 
and chronic inflammation than with HIV infection (Sulkowski and Thomas,  2003; 
Lucas  et al., 2007; Nath et al., 2008; Silverberg et al., 2009; Freiberg et al., 
2011; Valcour et al., 2011; Womack et al., 2011). 
The process of aging in many mammalian species, including rats, results in 
changes in immune responses, alterations in immunological phenotypes, and 
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ultimately increased susceptibility to infectious diseases, cancer, and 
autoimmune disorders (Dawson and Ross, 1999; Pahlavani and Vargas, 2001; 
Ropolo et al., 2001; Schmucker  et al., 2002).  Unraveling the mechanisms 
underlying the immunophenotypic changes associated with human HIV infection 
is now possible by utilizing a small animal model, the HIV-1 transgenic (HIV-1Tg) 
rat (Reid et al., 2001).  This animal model possesses human viral genes, 
including the HIV-1 provirus, but with the deletion of the gag and pol replication 
genes.  The HIV-1Tg rat exhibits similar clinical manifestations as HIV-positive 
humans, including wasting, skin lesions, cataracts, neurological and respiratory 
impairment, and changes in the immune system (Reid et al., 2001; Reid et al.,  
2004; Chang et al., 2007; Joshi et al., 2008), suggesting that the HIV-1Tg rat 
model is useful for studying HIV-1-infected patients on highly active anti-retroviral 
therapy (HAART) (Peng et al., 2010).  In the last decade, many reports have 
demonstrated that HIV-1Tg rat is a valuable model for studying neuroAIDS 
(Chang et al., 2007; Chang and Connaghan, 2012; Homji et al., 2012).  The HIV-
1Tg rat is, therefore, an ideal small animal model for studying the immunological 
alterations and pathology associated with chronic HIV-1 infection during aging. 
Viral gene expression has been detected in the lymph nodes, spleen, 
thymus, and blood of the HIV-1Tg rat,  similar to HIV infected humans (Reid et 
al., 2001; Reid et al., 2004).  HIV-specific transcripts (7-, 4-, and 2-kb) were 
present in spleen, kidney, and thymus, and highest in axillary lymph nodes.  
Further analysis revealed that the gp120 protein was present in macrophages as 
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well as B and T cells derived from splenic lysates. In addition, it has been 
reported that the viral proteins, tat, gp120, nef, and vif, in the spleen of 2-3 mo 
old HIV-1Tg rats is higher than in 10-11 mo old animals (Peng  et al., 2010).   
Although the HIV-1Tg rat spleen is normal in size, this animal did exhibit a loss of 
cells in the periarterial lymphatic sheath (PALS), larger marginal zones, follicular 
hyperplasia, and apoptosis of endothelial cells.  However, when immunized with 
keyhole limpet hemocyanin (KLH) to analyze immune cell function, there was no 
significant difference in anti-KLH-specific titers and a reduced induration seen in 
the delayed type hypersensitivity (DTH) response, suggesting that the HIV-1Tg 
rats have abnormal T helper (Th1) responses but, normal Th2 responses (Reid 
et al., 2001; Reid et al., 2004).   
In older HIV-1Tg rats (12-15 mo old), the CD4+ T cell population displays 
altered CD28 function, reduced anti-apoptotic Bcl-xL expression, reduced IL-2, 
and induced apoptosis (Yadav et al., 2006).  Mature HIV-1Tg rats also have 
decreased CD4+ and CD8+ effector and memory cells and an increased number 
of naïve cells (Reid et al., 2001; Reid et al., 2004).  These finding suggest that 
aging may influence immune function of T cell populations in the HIV-1Tg rat. 
 In order to explore the effect of aging on immune cell responses, determine 
the phenotypic changes associated with genotype, and establish 
immunophenotypic profiles in this small animal model of HIV, a polychromatic 
flow cytometry approach was employed in this study.  Whole blood and spleen 
from wild-type F344 and HIV-1Tg rats were grouped by age of 2 mo, 5-6 mo, and 
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18-20 mo.  Samples were analyzed for changes in immune cell populations, 
including B cells, T cells, T helper, T cytotoxic, neutrophil, and monocyte 
subtypes, classical and non-classical as defined in recent publications (Sengupta 
2013; Zhou et al., 2013). 
HIV-1Tg rats also display altered pro-inflammatory and anti-inflammatory 
cytokine and chemokine expression when treated with lipopolysacaride in the 
endotoxin tolerance (ET) model (Homji et al., 2012). Although the mechanism 
causing ET appears elusive, evidence suggests that ET produces a 
downregulation of inflammatory cytokines and an upregulation of anti-
inflammatory cytokines (Biswas and Lopez-Collazo,  2009).  This led us to 
investigate whether the immune cell profile and responses are compromised with 
aging in the HIV-1Tg rat. Using the ET model, animals were rendered tolerant by 
exposure to two low doses of lipopolysaccharide (LPS) and then challenged with 
a high dose of LPS as previously described (Chen  et al., 2005; Homji  et al., 
2012).  Blood, spleen and lymph nodes of HIV-1Tg rats and age-matched F344 
control rats were analyzed for changes in immunophenotype with LPS treatment 
related to age and genotype.  In addition, age-related changes in immune 
function were determined by examining cytokine and chemokine production in 
the LPS treated animals.  
The results of this study will provide evidence of the effects of aging on 
immune cellular profile and function in the HIV-positive population compared to 
non-infected individuals.  This information will be helpful in determining the best 
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treatment for HIV-infected individuals based on multiple factors, including 
immune cell profiles, cellular responses, and the patient’s age. 
 
  
6  
Materials and Methods 
 
 
Animals: 
All animals were purchased from Harlan Co. (Indianapolis, IN) at 
approximately 4-8 wks. of age, and maintained in ventilated cages up to 20 mo of 
age.  Male wild-type (F344) and HIV-1 transgenic (HIV-1Tg/F344) rats were 
grouped according to age.  All animal experiments were carried out in Seton Hall 
University’s Animal Care Facility.  Animal care and experiments were performed 
in accordance with the Animal Welfare Act and Public Health Service Policy.  
Approval was obtained from the Institutional Animal Care and Use Committee 
prior to the start of experiments. Euthanasia, when necessary, was performed 
using carbon dioxide asphyxiation and cervical dislocation.  
 
Flow cytometry:  
Whole blood was collected at 2, 5-6, 12, and 18-20 mo of age from the rat 
tail vein into Becton Dickinson (BD) lithium heparin tubes (BD 365965).  Twenty 
microliters of blood was blocked for non-specific staining with 0.25 µg anti-rat 
CD32 (BD 550271) for 5 min.  Fluorescently labeled antibodies were added 
according to the manufacturer’s protocol.  Cells were treated with antibodies and 
labeled as follows: B cells (CD45RA, BD 561624), T cells (CD3, BD 557354), T 
helper cells (CD4, BD 554839), T cytotoxic cells (CD8a, BD 558824), neutrophils 
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(RP-1, BD 550002), monocyte population (CD43-AF647, Biolegend 202810; 
CD172, BD 552298; CD11b, BD 562105), and isotype-matched gating controls.  
Cells were treated for 30 min at 4°C with fluorescently labeled antibodies, and 
then centrifuged for 5 min at 300 xg.  The supernant was removed and the blood 
was treated with 1X cell lysing solution (BD 349202) for 10 min at room 
temperature (RT).  Cells were centrifuged for 5 min at 300 xg, then washed with 
FACS buffer (PBS, 0.1% BSA, 25 mM HEPES).  All samples were re-suspended 
in FACS buffer, prepared in duplicate, and 30,000 events were acquired on the 
BD Fortessa.  Immune cells populations were gated as follows: B cells 
(CD45RA+/CD3-), T cells (CD3+/CD45RA-), T helper cells (CD3+CD4+), T 
cytotoxic cells (CD3+CD8+), neutrophils (RP-1+), and classical 
(mononuclear/CD172+/CD43+) and non-classical (mononuclear/CD172+/CD43++) 
monocytes, as described previously (Zhou  et al.,  2013). 
Spleen samples were collected at time of sacrifice from 2 mo, 5-6 mo and 
18-20 mo old animals.  Spleen cells were isolated by pulverizing the spleen 
tissue through 100 µm nylon mesh (Fisher, 22363549), washing in FACS buffer, 
then treating them with red blood cell lysing buffer (Gibco #A10492-01) for 5 min 
at RT.  The cells were washed with FACS buffer, centrifuged, and counted.  The 
spleen cells (106 cells/sample) were stained with fluorescently labeled antibodies 
as described for whole blood. 
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Lipopolysaccharide (LPS) administration:  
Male HIV-1Tg and F344 rats were grouped by age and genotype (N = 
5/group): 2, 5-6 and 18-20 mo of age.  Treatment with LPS in each group to 
induce ET was completed as previously established in our laboratory using the 
HIV-1Tg rat model (Chen et al.,  2005; Homji et al.,  2012).  Briefly, animals were 
administered IP a non-pyrogenic dose of 250 µg/kg LPS (from E. Coli 055:B5, 
Sigma, L2880) on day 1 at 0h and 10h, respectively and a challenge injection of 
5 mg/kg LPS at 24 h.  Animals treated with LPS are designated as “LPS treated” 
in this study.  Age- and genotype-matched vehicle control animals were injected 
with 0.9% saline on the same time schedule as LPS treated rats, and are 
designated as “Control” in this study. 
 
Cytokine and chemokine analysis: 
To measure cytokine levels in the LPS treated animals, the rats were 
sacrificed 2 h post final LPS treatment (at 26 h).  Spleen and lymph nodes 
(axillary and mesenteric) were isolated and stored at −80°C.  Tissue was 
homogenized in lysis buffer containing 5 mM Tris-HCl (Boston BioProducts, BM-
320), 2 mM EDTA (Boston BioProducts, BM-150), 1% Triton X-100 (Sigma, 
T6878), and 1 vial protease inhibitor cocktail (Sigma P2714) at a ratio of 1:10 
(tissue:buffer).  Samples were homogenized with a Polytron PT2100 for 30s on 
ice, centrifuged at 6,800 rcf for 5 min at 4° C, and supernants were collected.  
Total protein concentrations were measured using a micro BCA Protein Assay Kit 
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(Pierce #23235).  Blood was collected into serum separation tubes (BD, 365967), 
spun down, and the serum was separated.  Serum (30 µl) was diluted 1:4 with 
Diluent 42 (MesoScale Discovery).  The levels of ten cytokines and chemokines 
[interferon (IFN)-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, KC/GRO, IL-10, IL-13, tumor 
necrosis factor-α (TNF-α)] were determined from 100 µg of spleen., or diluted 
serum using the rat pro-inflammatory V-plex kit (panel 1, MesoScale Discovery), 
according to the manufacturer’s instructions. Due to limitations of tissue sample, 
only   Il-6 and TNF-α levels were examined in 50µg of lymph node total protein.  
All samples were run in duplicate, and the mean and standard deviation was 
calculated. 
 
Western blot analysis: 
Tissue was homogenized and total protein concentrations were 
determined as described above.  Protein (40 µg) was added to 2X LDS sample 
buffer (Invitrogen, NP0007, 4X diluted 1:1 with water) with 5% reducing agent 
(Invitrogen, NP0004), and heated for 7 min at 95°C.  Proteins were resolved on a 
4-12% Bis-Tris gel (Novex #NP0322) and transferred onto a nitrocellulose 
membrane (Novex, 1B3011002) using the Ibot system.  Membranes were 
blocked for 1 h at RT with TBS (Tris-buffered saline, ph 7.4, Boston BioProducts, 
BM-300) containing 0.05% Tween 20 (Fisher, BP337-500) and 1% bovine serum 
albumin (BSA, Gemini, 700-100P).  Membranes were incubated with primary 
TNF-α antibody (1:1000, Abcam, ab66579) or IL-6 (1:1000, Abcam, ab6672), 
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with β-actin (1:1000, cell signaling #8H10D10) as a loading control, followed by 
secondary antibodies for visualization (1:15,000, goat anti-mouse IgG, Licor 827-
08364; donkey anti-rabbit IgG, Licor 926-68073), diluted in blocking buffer (Licor, 
927-40000).  Proteins were analyzed on the Odyssey infrared imaging system for 
detection and quantification.  The integrated intensity signal of β-actin was used 
to normalize the signal of TNF-α and IL-6.  The percentage change in normalized 
protein was calculated by comparison to the F344 age-matched vehicle control.  
  
Statistical analysis: 
Flow cytometry analysis was performed using DIVA 6.1.3, FlowJo V10 
and Graph Pad Prism 5 software.  All data are presented as the mean ± SD.  
Statistical differences among the groups were assessed by a one-way ANOVA, 
and post hoc multiple comparisons were performed using the Bonferroni multiple 
comparisons test.  The significance level was set at p < 0.05. 
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Results 
 
 
Immunophenotypic analysis of untreated peripheral blood cells in aging 
rats 
Immune cell populations from whole blood were gated as illustrated in Fig 
1.  CD3+ T cell lymphocytes (Fig. 2A) were significantly increased in 2 mo old 
HIV-1Tg rats compared to age-matched F344 animals.  However, T cell 
percentages decreased in both groups during aging, but to a greater extent in 18 
mo old HIV-1Tg rats.  The percentage of T helper cells (CD3+/CD4+) from the 
HIV-1Tg rats was higher throughout the aging process, with a significant increase 
in 5-6 and 12 mo old animals (Fig. 2B).  There was a significantly lower 
percentage of T cytotoxic cells (CD3+/CD8+) in the 6, 12, and 18 mo old HIV-1Tg 
rats compared to the age-matched control rats (Fig. 2C). 
  Flow cytometry analysis revealed that the percentage of B cells in both the 
HIV-1Tg and wild-type F344 rats was higher in the 2 mo old rats and decreases 
with aging (Fig. 2D).  
 The percentage of neutrophils was less than 10% in both the HIV-1Tg and 
F344 groups at 2, 5-6 and 12 mo of age.  However, the percentage of neutrophils 
increased significantly in the 18-20 mo old HIV-1Tg rats compared to the age-  
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Figure 1. Flow cytometry gating strategy for HIV-1Tg and F344 rat 
blood. 
Mononuclear, lymphocytes, and granulocytes were gated on FSC versus SSC. Cell 
surface antibodies were used to identify B and T cells,  T cytotoxic cells,  T helper 
cells, neutrophils, monocytes, and monocyte subtypes (classical and non-
classical). 
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Figure 2. Analysis of cell populations in whole blood from HIV-1Tg and 
F344 rats. 
Flow cytometry analysis of untreated HIV-1Tg immune cell populations (red line) and 
untreated F344 age-matched rats (blue line). (A) T cells (CD3+); (B) T helper cells 
(CD3+/CD4+);  (C) T cytotoxic cells (CD3+/CD8+);  (D) B cells (CD45RA+); (E) 
neutrophils; (F) monocytes; (G) classical monocytes (CD43+); (H) non-classical 
monocytes (CD 43++). N=5 rats/group. *p,0.05**p,0.01, ***p,0.001, ****p,0.0001.  
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matched controls (Fig. 2E).  There was a significantly lower percentage of 
monocytes (Fig. 2F) in the 2, 5-6, and 12 mo old HIV-1Tg rats compared to the 
F344 age-matched control animals, and which remained slightly lower throughout 
the aging process.  In the rat, CD43+ classical monocytes are similar to human 
CD14+CD16-, and CD43++ non-classical monocytes act like human 
CD14+CD16+cells.The percentage of classical monocytes in the HIV-1Tg rats 
declined at 12 mo of age compared to the control animals (Fig. 2G), whereas 
there was a slight but not significant increase in the percentage of non-classical 
monocytes in the HIV-1Tg rats at 12 mo of age (Fig. 2H). 
 
Immunophenotypic analysis of peripheral blood cells in LPS treated aging 
rats  
As a model molecule, LPS is commonly used to examine inflammatory 
response and immunophenotypic changes in animal models. Flow cytometry 
analysis of whole blood showed that the percentage of CD3+ T cell lymphocytes 
was significantly higher in both untreated and LPS-treated 2 and 5-6 mo old HIV-
1Tg rats compared to age-matched F344 rats (Fig. 3A).  However, T cell 
percentages decreased in 18 mo old HIV-1Tg and F344 rats.  The percentage of 
T helper cells (CD3+/CD4+) in the LPS-treated HIV-1Tg rats was significantly 
higher throughout the aging process compared to the F344 rats (Fig. 3B).  
Conversely, the percentage of T cytotoxic cells (CD3+/CD8+) was significantly 
lower in the LPS treated 5-6 and 18-20 mo old HIV-1Tg rats compared to the 
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LPS treated F344 animals (Fig. 3C). The percentage of B cells was not 
significantly different in the age matched HIV-1Tg and F344 control or LPS 
treated groups (Fig.3D). 
 The percentage of neutrophils remained low in the control blood of both 
the HIV-1Tg and F344 rats, but increased in response to LPS in both the HIV-
1Tg and F344 rats in all age groups (Fig. 3E).  There was no significant  
difference in the percentage of monocytes in the control and LPS treated HIV-
1Tg compared to the age and treatment matched F344 group.  However, the 
percentage of classical monocytes was significantly lower in 18-20 mo control 
HIV-1Tg rats compared to the age-matched control F344 animals (Fig. 3G).  
Conversely, the percentage of non-classical monocytes was significantly 
increased in 18-20 mo control HIV-1Tg rats compared to age matched control 
F344 animals. (Fig. 3H).  
 
Immunophenotypic analysis of immune cells from the spleens of LPS 
treated aging rats  
The distribution of immune cells in the spleens of HIV-1Tg rats, with and without 
an LPS treatment, was compared to age-matched F344 rats using flow cytometry 
analysis.  The percentage of CD3+ T cell lymphocytes was significantly increased 
in 5-6 mo old LPS-treated HIV-1Tg rats compared to the F344 
16  
 
 
Figure 3. Analysis of cell populations in whole blood from aging HIV-
1Tg and F344 rats, with and without LPS treatment. Flow cytometry 
analysis of HIV-1Tg cell populations (red bars) and F344 age-matched control rats 
(blue bars). Solid bars indicate control samples and bars with striped lines indicate 
samples that have been treated with LPS. (A) T cells; (B) T helper  cells; (C) T cytotoxic 
cells; (D) B cells; (E) neutrophils; (F) monocytes;  (G) classical monocytes; (H) non-
classical monocytes. N=5 rats/group. *p,0.05, **p,0.01, ***p,0.001, ****p,0.0001.  
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animals, and significantly decreased in 18-20 months old HIV-1Tg rats (Fig. 4A).  
The percentage of T helper cells (CD3+/CD4+) was significantly higher in the 2 
mo old control HIV-1Tg rats compared to the age-matched F344 animals (Fig. 
4B).  There was a significantly lower percentage of T cytotoxic cells (CD3+/CD8+) 
in the 18-20 mo old LPS treated HIV-1Tg rats compared to age matched LPS 
treated F344 rats (Fig. 4C).   
The percentage of B cells was significantly higher in the 18-20 mo old 
LPS-treated HIV-1Tg rats compared to age matched LPS treated F344 rats (Fig. 
4D). The percentage of neutrophils in the spleen was significantly decreased in 
the 2 mo old LPS-treated HIV-1Tg rats compared to the age-matched F344 
control animals (Fig. 4E)  There was a significantly lower percentage of 
monocytes in the 18-20 mo old LPS-treated HIV-1Tg rats compared to LPS 
treated age matched F344 rats (Fig. 4F). However, the percentage of classical 
monocytes (Fig.4G) or non-classical monocytes (Fig 4H) was not significantly 
different when comparing age and treatment matched HIV-1Tg and F344 rats.   
18  
  
Figure 4. Immune cells in the spleens of aging HIV-1Tg and F344 rats, with 
and without LPS treatment. Flow cytometry analysis of immune cells from the 
spleens of HIV-1Tg rats (red bars) and F344 age-matched control rats (blue 
bars). Solid bars indicate control samples and bars with striped lines indicate 
samples that have been treated with LPS. (A) T cells; (B) T helper cells; (C) T 
cytotoxic cells; (D) B cells; (E) neutrophils; (F) monocytes; (G) non-classical 
monocytes; (H) classical monocytes. N=5 rats/group. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
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Cytokines and chemokines in the serum, spleen, and lymph nodes of LPS-
treated aging rats 
The protein levels of IFN-γ, IL-1β,IL-2, IL-4, IL-5, IL-6, KC/GRO, IL-10, IL-
13, and TNF-α in the serum, spleen, and lymph nodes of HIV-1Tg and F344 age-
matched rats treated with LPS or saline (control) were determined using an 
electrochemiluminescent assay.  There was no difference in the levels of IL-2, 
INF-γ, IL-4, and IL-13 in the serum of the LPS- and saline-treated HIV-1Tg and 
F344 rats (Fig. 5A-D).  Although not significant, there was a slight decrease in 
the IL-5 levels associated with increased age in both the untreated F344 and 
HIV-1Tg rats; however, IL-5 was elevated in all the LPS-treated groups (Fig. 5E).  
There was no difference in IL-10 levels in any age group in either the control or 
LPS-treated F344 rats, and no difference in IL-10 in the 2 mo old control and  
LPS-treated HIV-1Tg rats.  However, there was an increase, although not 
significant, with IL-10 in the 5-6 mo LPS-treated HIV-1Tg rats as well as the 
control and LPS-treated18-20 mo old HIV-1Tg rats compared to the treated and 
age-matched F344 rats (Fig. 5F).  IL-1β in both the control HIV-1Tg and F344 
rats was below detection levels for this assay (<3 pg/ml).  The IL-1β levels in 
both the LPS-treated F344 and HIV-1Tg rats declined with increased age (Fig. 
5G).  KC/GRO levels were low in both untreated HIV-1Tg and F344 rats; 
however, KC/GRO levels increased significantly in 5-6 and 18-20 mo old HIV-
1Tg rats treated with LPS compared to age matched LPS treated F344 rats (Fig. 
5H).  Both IL-6 and TNF-α level were minimal at all ages in both the control HIV- 
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Figure 5.  Cytokines and chemokines in the serum of aging HIV-1Tg and 
F344 rats, with and without LPS treatment.  Cytokine and chemokine levels of 
serum from HIV-1Tg rats (red bars) compared to F344 age-matched controls 
(blue bars). Solid bars indicate control (saline) treated samples and bars with 
striped lines indicate samples treated with LPS. (A) IL-2; (B) IFN-γ; (C) IL-4; (D) 
IL-13; (E) IL-5; (F) IL-10; (G) IL-1β; (H) KC/GRO; (I) IL-6 and (J) TNF-α.           
N=5 rats/group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 
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1Tg and F344 animals.  There was a significant increase in both IL-6 and TNF-α 
level in the serum of LPS-treated HIV-1Tg rats at 18-20 mo of age compared to 
the age-matched control and LPS-treated F344 rats (Figs. 5I and 5J). 
Spleen samples showed similar levels of IL-2, INF-γ, IL-4, and IL-5 in age 
and treatment matched HIV-1Tg and F344 rats during aging (Figs. 6A, B, C, and 
E).  IL-13 increased in response to LPS in both the F344 and HIV-1Tg rats (Fig. 
6D).  The increase in IL-10 in response to LPS was similar in the 2 and 5-6 mo 
old F344 rats, but had declined at 18-20 mo of age (Fig. 6F).  IL-10 in the HIV-
1Tg rats was increased in response to LPS at all ages, and was significantly 
higher at 18-20 mo of age compared to age-matched F344 animals (Fig. 6F).   
IL-1β levels were comparable in the spleen of control HIV-1Tg and F344 rats, 
and increased in response to LPS in both groups.  However, at 5-6 mo of age, 
the level of IL-1β was significantly lower in the LPS-treated HIV-1Tg rats 
compared to the treated age-matched F344 rats (Fig. 6G).  KC/GRO 
concentrations were similar in control HIV-1Tg and F344 rats, and increased in 
response to LPS in both groups.  The LPS-induced levels of KC/GRO appeared 
to decrease with age in the F344 rats, whereas KC/GRO remained significantly 
higher at 18-20 mo of age in the HIV-1Tg animals (Fig. 6H).  IL-6 and TNF-α 
were at basal levels in the spleens of the control HIV-1Tg and F344 rats. 
However, both IL-6 and TNF-α increased significantly in response to LPS in the 
spleens of the 18-20 mo old HIV-1Tg rats compared to age and treatment   
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Figure 6.  Cytokines and chemokines in the spleens of aging HIV-1Tg and 
F344 rats, with and without LPS treatment.   Cytokine and chemokine levels of 
spleen protein from HIV-1Tg rats (red bars) compared to F344 age-matched 
controls (blue bars). Solid bars indicate control (saline) treated samples and bars 
with striped lines indicate samples treated with LPS. (A) IL-2; (B) IFN-γ; (C) IL-4; 
(D) IL-13; (E) IL-5; (F) IL-10; (G) IL-1β; (H) KC/GRO; (I) IL-6 and (J) TNF-α.            
N=5 rats/group.    *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 
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matched F344 rats (Figs. 6I and 6J).   
Low levels of IL-6 and TNF-α were found in the lymph nodes in control 
HIV-1Tg and F344 rats as well as in 2 and 5-6 mo old LPS-treated HIV-1Tg and 
F344 animals (Figs. 7A and B).  There were significantly higher levels of IL-6 and 
TNF-α in the lymph nodes of LPS treated 18-20 mo old HIV-1Tg rats compared 
to age-matched LPS treated F344 rats. 
 
IL-6 and TNF-α protein analysis 
The IL-6 protein signal was comparable in both the control treated 2 and 5-6 mo 
old HIV-1Tg and F344 rats; however, there was a slight increase in the IL-6 
signal in the spleens of the control 18-20 mo old HIV-1Tg rats compared to the-
age matched control F344 rats (Fig. 8A).  IL-6 protein increased with age in the 
LPS-treated HIV-1Tg rats, with a significant increase seen in the 18-20 mo old 
HIV-1Tg rats compared to the age-matched LPS-treated F344 rats (Fig. 8B). 
There was a significant increase in TNF-α levels in the spleens of the 18-20 mo 
old HIV-1Tg control rats (Fig. 8C), and no significant difference in TNF-α levels in 
the 2 mo and 5-6 mo control HIV-1Tg, and 2 mo, 5-6 mo and 18-20 mo control 
F344 animals.  There was no difference in the TNF-α protein levels following LPS 
treatment in the 2 mo old HIV-1Tg and F344 rats, but a slight decrease in both 
groups at 5-6 mo of age.  There was a significant increase in TNF-α level in both 
the LPS treated HIV-1Tg and F344 rats at 18-20 mo of age compared to the age- 
matched F344 controls (Fig. 8D). 
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Figure 7. IL-6 and TNF-α in lymph nodes of aging HIV-1Tg and F344 rats, 
with and without LPS treatment. 
Pro-inflammatory cytokines, (A) IL-6 and (B) TNF-α, were examined in the lymph 
nodes of HIV-1Tg (red bars) and age-matched F344 control rats (blue bars), with 
and without LPS treatment. Solid bars indicate control samples and bars with 
striped lines indicate samples treated with LPS. N=5 rats/group.  *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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Figure 8. IL-6 and TNF-α in the spleens of aging HIV-1Tg and F344 rat 
spleen, with and without LPS treatment. 
The integrated intensity of TNF-α and IL-6 protein from the spleens of HIV-1Tg 
(red bars) and F344 age-matched control rats (blue bars), with and without LPS 
treatment, was measured using Western blot analysis and normalized to β-actin 
protein. (A) IL-6 after saline treatment; (B) IL-6 after LPS treatment; (C) TNF-α 
after saline treatment; (D) TNF-α after LPS treatment. N=5 rats/group.*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 
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Discussion 
 
 
It is well known that aging causes alterations in immune responses, in 
general, with increased susceptibility to many infectious diseases (Aberg, 2011; 
Barrett et al.,  2012; Cavanagh et al.,  2012; Goronzy and Weyand,  2012; Kogut, 
et al.,  2012; Rymkiewicz  et al.,  2012).  Understanding the changes in immune 
responses in HIV-positive individuals is further complicated when factors such as 
age and disease progression are taken into consideration.  Utilizing the HIV-1Tg 
rat, we were able to demonstrate that, in this animal model of human HIV-1-
positive patients receiving HAART, alterations in immune cell populations and 
response to an LPS challenge occur with aging. 
Flow cytometric analysis of untreated blood revealed that, in the HIV-1Tg 
rat, there is a decrease in T cells, particularly T cytotoxic cells, but an increase in 
T helper cells with increased aging.  Interestingly, the untreated F344 rat did not 
display changes in the percentage of T cells within the lymphocyte due to age 
and showed percentages of 52-55%.  This result is similar to a study by 
Schmucker et al. in which they compared young adult (4-6 mo old) and 
senescent (24-26 mo old) F344 rats finding that the percentage of the T cell 
populations within the blood were consistent regardless of age (Schmucker et al.,  
2002).  These results suggest that age of HIV-1Tg may play a role in the 
decrease of T cell populations that are not displayed in the F344 animals.  
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 In healthy humans,  CD14+CD16-  cells represent 90-95% of the total 
monocyte population in the blood and are described as “classical”, while the 
remaining 5-10%  are proinflammatory monocytes (CD14+CD16+)  termed “non-
classical” (Strauss-Ayali  et al.,  2007).  In the rat, two subsets of monocytes 
have been described based on chemokine receptor expression and CD43 
amounts. CD43+ are similar to human CD14+CD16- classical monocytes, while in 
the rat CD43++ monocytes act like human non-classical CD14+CD16+ populations 
(Grau et al.,  2000; Strauss et al.,  2007). Monocytes are precursors for 
macrophage and dendritic cell populations, and have important functions in 
innate and adaptive immunity throughout inflammation (Tacke and Randolph,  
2006).  Increases in non-classical monocytes have been associated with 
infections, including HIV and aging. Non-classical monocytes produce higher 
amounts of inflammatory cytokines including TNF-α protein, while classical 
monocytes produce a broad range of cytokines including IL-10 and IL-6 (Wong  
et al.,  2011).   
The percentages of monocytes in this study were decreased in the 
untreated HIV-1Tg rats compared to the F344 animals, but increased with aging.  
Interestingly, the percentage of classical and non-classical monocytes was 
similar throughout aging in the HIV-1 and F344 rats.   Perhaps the changes 
exhibited in the monocyte populations and cytokine increases associated with 
HIV-1 aging may be related to alterations with the macrophage or dendritic 
populations not detected in these studies.  These results, however, demonstrated 
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that untreated HIV-1Tg rats display alterations in immunophenotype due to aging 
that are not evident in age-matched F344 rats.  Thus, the persistent presence of 
HIV-1 viral proteins appears to lead to aging dependent immunomodulation. 
LPS is a glycolipid component of gram-negative bacteria commonly used 
to study inflammatory responses and cytokine and chemokine changes (Schletter  
et al.,  1995; Fujihara  et al.,  2003; Biswas and Lopez-Collazo,  2009).  A 
balance in pro-inflammatory and anti-inflammatory responses is imperative in 
achieving an appropriate immune response to a stimulus.  An imbalance 
between pro-inflammatory and anti-inflammatory cytokines can cause adverse 
biological events, such as septic shock (Biswas and Lopez-Collazo,  2009).  
Repeated exposure to an endotoxin such as LPS can cause endotoxin tolerance 
(ET), in which there is an increase in anti-inflammatory cytokines and a decrease 
in pro-inflammatory cytokines (Biswas and Lopez-Collazo,  2009).  A recent 
study reported that ET causes an imbalance in the cytokine/chemokine response 
in an HIV-1Tg animal (Homji et al.,  2012).  While innate immunity is deregulated 
in both HIV infection and ET (Lester et al.,  2009), identifying changes in immune 
responses that are also related to age may provide useful information in treating 
bacterial and other infections in the HIV patient.  
Aging is linked with heightened amounts of circulating cytokines and 
proinflammatory markers (Michaud et al.,  2013).  Increased levels of the 
proinflammatory cytokines IL-6 and TNFα, along with IL-1 and C-reactive protein, 
have been associated with an elevated risk of morbidity and mortality found in 
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aging population (Michaud et al.,  2013).  In humans, a condition referred to as 
‘inflamm-aging’, exhibits an increase in IL-6 and TNF-α which occurs with aging 
(Franceschi et al.,  2000; Wolf  et al., 2012).  In mature HIV-positive individuals, 
elevated levels of IL-6 and TNF-α have been reported (Nixon and Landay,  
2010).  Immunoscenescence or aging of the immune system caused by a 
prolonged antigen burden could be accelerated in HIV-positive individuals 
(Franceschi  et al.,  2007; Vasto  et al., 2007; Smith et al.,  2013).  
 IL-6 is secreted by T cells and macrophages and has a role in 
inflammation and aging whereas TNF-α is mainly secreted by macrophages 
(Michaud  et al., 2013).  KC/GRO is produced by macrophages and is involved in 
neutrophil activation. In our study, there was a significant increase in the 
percentage of neutrophils in the blood of untreated 18 mo HIV-1Tg rats and 
increases in monocyte populations with aging.  IL-10 inhibits the synthesis of 
many cytokines that have a role in suppression of Th1 pro-inflammatory 
responses and phagocytic uptake.  The cytokines IL-6 and TNF-α, along with the 
CXC chemokine, KC/GRO, were significantly elevated in the blood and spleen 
protein of 18-20 mo old LPS treated HIV-1Tg rats.  In addition, there was 
increased IL-6 and TNF-α protein expression in the lymph nodes.  IL-10 levels 
were increased in the spleen of LPS-treated 18-20 mo old HIV-1Tg rats 
compared to LPS-treated and age-matched F344 rats.  These results further 
indicate that age may play a role in the alterations of the immune cell responses 
in HIV-positive individuals.   
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In HIV-infected patients, anti-retroviral therapies have been successful in 
controlling viral replication, allowing those individuals to achieve a relatively 
normal life span (Manfredi,  2004; Manfredi and Calza,  2004; Gebo,  2006).  
Viral proteins, however, are capable of independently inducing organ dysfunction 
and affecting host target cells (T cells and macrophages), resulting in the clinical 
manifestations of AIDS (van Maanen and Sutton,  2003; Joshi et al.,  2008; Peng  
et al.,  2010). In addition, Peng, et al (2010) observed that the HIV-1Tg rat died at 
an earlier age than F344 rats. As an HIV-infected individual matures, immune cell 
function may be compromised even more.  Age may, therefore, be a factor in 
determining appropriate therapies for both younger and older HIV-infected 
patients.  
These results suggested that the HIV-1Tg rat displayed immune 
alterations in T cells, neutrophils and monocytes with aging.  Thus, in addition to 
serving as a rodent neuroAIDS model to study the HIV patients given HAART, 
our current studies suggest that the HIV-1Tg rat could be an ideal model to study 
aging associated immune alterations of HIV patients. 
Future studies following the immunological changes in T cells, neutrophils 
and monocytes with aging, may focus on investigating specific immune subtypes, 
not examined in this current report. Using flow cytometry, immunophenotypic 
analysis of cell populations such as activated and regulatory T cell populations, 
mature and immature monocytic derived dendritic cells, natural killer (NK), and B 
cell subtypes (naïve, mature, memory) may exhibit additional changes in the 
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aging HIV-1Tg rat. Further analysis of cellular response at the protein level may 
include surveying additional cytokines and chemokines, not currently examined, 
with western blots and/or electrochemiluminescent assays. These results may 
unearth a specific cellular subtype which may have an important role in aging of 
the HIV-1Tg rat. 
In addition, it would be interesting to inspect immunophenotype and 
cellular response in an acute immune challenge model not examined in this 
report. Aged animals treated with a single dose of LPS, may respond differently 
compared to the ET model used in this study. In vitro treatments of splenocytes 
or whole blood from aged animals challenged with agents such as LPS or 
phorbol myristate acetate (PMA), may display different cellular response in the 
aged HIV-1Tg rat compared to the F344 animals.  
Founded on the results established in this report, potential studies may 
include exploring the immunological effects of HIV and aging within the brain. 
Cognitive impairment linked to human HIV has been demonstrate in the HIV-1Tg 
rat (Rao et al, 2011). Rao showed that protein and mRNA in the brains of 7-9 mo 
old animals displayed increases in cytokines, including TNF-α, along with 
changes in the microglial and  the macrophage marker CD11b. A detailed study 
examining the protein and mRNA levels of neuroinflammatory markers in the 
aged (18-20 mo) rat may reveal alterations in the HIV-1Tg rat brain not displayed 
in F344 rats. In addition, evidence suggests that LPS treatment may increase 
RNA turnover of  IL-6 and TNFα along with corticosterone  levels in the rat brain 
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with ET treatment (Chen  et al.,  2005). Aged HIV-1 Tg rat brains treated with 
LPS may be examined at the protein and mRNA level to understand changes 
occurring in the aged brain.  Developmental learning, such as associated with 
dendritic spine turnover, may be altered in the aging HIV-1Tg rat. Cognitive 
animal tests, such as the Morris water maze test, may reveal further changes in 
the aging rat. Perhaps these and other differences with the molecular mechanism 
underlying the age-related neuronal and immune compromised status many be 
revealed in the aging HIV-1Tg rats. 
Another area to explore with the HIV-1Tg rat involves the cellular aging 
pathway and structural alterations to telomeres. It is known that shortening of the 
telemetric sequences and telomeres is associated with increased age (Abrass et 
al, 2012). Data suggests that human immune cell types, including effector CD8 T 
cells, display shortened telomeres and lack of telomerase activity in seniors with 
decreased vaccine response, bone deficiency, neurocognitive regression and 
cardiovascular illness. Immunohistochemistry experiments focusing on 
measuring telomeres through the aging process in HIV-1Tg compared to F344 
rat may provide evidence that HIV status influences telomere shortening. 
Exploring the structural attributes of the telomeres in immune cells such as T cell, 
monocytes and neutrophils in the HIV-1Tg rat may reveal changes associated 
with increased aging.  
Understanding HIV status and relating age related consequences in the 
HIV-1Tg rat may provide new avenues into treating the aging human population 
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currently infected with HIV. Treatments specifically targeting alterations in IL-6 
and TNFα may prevent or delay senescence in the aging HIV patient. The 
findings from this study provide evidence pointing to age-related alterations in 
immune cell function in the HIV-positive population. This information could be 
important in the development of novel therapeutic treatments for HIV-infected 
individuals based on multiple factors, including immune cell profile, cellular 
responses, and age of the patient. 
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